Summary: | Mingfeng Shao, Ziqiang Yu, Jianan Zou Department of Urology, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei City, Anhui Province 230031, People’s Republic of ChinaCorrespondence: Jianan ZouDepartment of Urology, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, No. 117, Meishan Road, Hefei City, Anhui Province 230031, People’s Republic of ChinaTel +86 551-62850073Email zjmsusooyes35@163.comBackground: lncRNA-SNHG16 was identified as an oncogene in many cancers, but its involvement in prostate carcinoma is unknown.Material and Method: Expression of lncRNA-SNHG16 and glucose transporter 1 (GLUT-1) in 52 prostate carcinoma tissues and 36 normal prostate tissues was analyzed by RT-qPCR. Transfections were performed to analyze gene interactions. Cell proliferation was analyzed by cell proliferation assay.Results: Overexpression of lncRNA-SNHG16 effectively distinguished prostate carcinoma patients from normal ones. Expression levels of lncRNA-SNHG16 and GLUT-1 mRNA were significantly and positively correlated across prostate carcinoma tissues. In vitro cancer cell experiments revealed that lncRNA-SNHG16 siRNA silencing downregulated the expressions of GLUT-1 and reduced glucose uptake. lncRNA-SNHG16 siRNA silencing also significantly inhibited prostate carcinoma cell proliferation. However, lncRNA-SNHG16 siRNA silencing did not affect the normal prostate.Conclusion: In conclusion, lncRNA-SNHG16 might be a possible treatment target for prostate cancer.Keywords: prostate carcinoma, SNHG16, glucose transporter 1
|